- Home
- BEAT vs CMRX Comparison
BEAT vs CMRX Comparison
Compare BEAT & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- CMRX
- Stock Information
- Founded
- BEAT 2015
- CMRX 2000
- Country
- BEAT United States
- CMRX United States
- Employees
- BEAT 20
- CMRX N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- CMRX Health Care
- Exchange
- BEAT Nasdaq
- CMRX Nasdaq
- Market Cap
- BEAT 74.1M
- CMRX 77.1M
- IPO Year
- BEAT 2021
- CMRX 2013
- Fundamental
- Price
- BEAT $2.66
- CMRX $2.84
- Analyst Decision
- BEAT Buy
- CMRX Strong Buy
- Analyst Count
- BEAT 1
- CMRX 2
- Target Price
- BEAT $8.00
- CMRX $8.50
- AVG Volume (30 Days)
- BEAT 282.2K
- CMRX 11.2M
- Earning Date
- BEAT 11-07-2024
- CMRX 11-07-2024
- Dividend Yield
- BEAT N/A
- CMRX N/A
- EPS Growth
- BEAT N/A
- CMRX N/A
- EPS
- BEAT N/A
- CMRX N/A
- Revenue
- BEAT N/A
- CMRX $159,000.00
- Revenue This Year
- BEAT N/A
- CMRX N/A
- Revenue Next Year
- BEAT N/A
- CMRX $1,690.28
- P/E Ratio
- BEAT N/A
- CMRX N/A
- Revenue Growth
- BEAT N/A
- CMRX N/A
- 52 Week Low
- BEAT $1.06
- CMRX $0.75
- 52 Week High
- BEAT $3.48
- CMRX $3.39
- Technical
- Relative Strength Index (RSI)
- BEAT 47.14
- CMRX 84.35
- Support Level
- BEAT $2.28
- CMRX $2.74
- Resistance Level
- BEAT $3.48
- CMRX $3.02
- Average True Range (ATR)
- BEAT 0.29
- CMRX 0.26
- MACD
- BEAT -0.05
- CMRX 0.18
- Stochastic Oscillator
- BEAT 37.83
- CMRX 77.13
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.